Source comparison
SS-31 Dosage for Exercise Performance: Protocol Comparison
0.1 mg/kg 90 minutes Time to exhaustion +3.2% (not significant) Sedentary adults Insufficient dose for measurable mitochondrial protection during exercise 0.25 mg/kg 60 minutes VO2 efficiency at submaximal load +4.8% (p < 0.05) Recreationally active Minimal ef
This comparison does not assign a generated winner or score.
- 0.1 mg/kg
- 90 minutes
- Time to exhaustion
- +3.2% (not significant)
- Sedentary adults
- Insufficient dose for measurable mitochondrial protection during exercise
- 0.25 mg/kg
- 60 minutes
- VO2 efficiency at submaximal load
- +4.8% (p < 0.05)
- Recreationally active
- Minimal effective dose. Benefit emerges only in sustained moderate-intensity work
- 0.4 mg/kg
- Time-trial performance (cycling)
- +6.2% (p < 0.05)
- Trained cyclists
- Optimal dose-timing combination for endurance performance in trained populations
- 0.5 mg/kg
- 120 minutes
- Post-exercise CK and recovery time
- −31% CK, −18% recovery time
- Resistance-trained athletes
- Maximal protective effect on muscle damage markers. No additional benefit above this dose
- 0.75 mg/kg
- Peak power output
- No change from baseline
- Mixed training status
- Dose exceeds cardiolipin binding capacity. Excess peptide cleared without additional effect
- 1.0 mg/kg
- All performance metrics
- No improvement over 0.5 mg/kg
- Trained endurance athletes
- Saturation reached at lower doses. Higher doses increase cost without increasing benefit